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Epstein–Barr virus (EBV)-associated tumors express a limited number of viral antigens but most of them express the latent membrane protein
2 (LMP2). This article describes a peptide derived from LMP2 (residues 396–404, designated LLL) as a potentially useful vaccine. This peptide
could at first be defined as an unlikely T cell target as it could not stabilize MHC surface expression in transporter associated with antigen-
processing (TAP)-deficient cells. Nevertheless, T lymphocytes reactive to LLL were detected in the peripheral blood of four EBV-seropositive
healthy individuals. We have constructed a chimeric molecule in which LLL was fused to the amino-terminal end of the β2 microglobulin (β2m).
Autologous dendritic cells constitutively expressing the LLLβ2m molecule were capable of expanding in vitro HLA-A2-restricted anti-LLL T
lymphocytes from the peripheral blood of one of the donors. These T lymphocytes exhibited cytolytic activity against target cells expressing the
chimeric molecules as well as against EBV-infected lymphoblastoid cells expressing natural LLL–MHC complexes.
© 2006 Elsevier Inc. All rights reserved.Keywords: T lymphocyte; CTL epitope; Epstein–Barr virus; VaccineIntroduction
Epstein–Barr virus (EBV) is a lymphotropic herpes virus
that is widespread in the human population. Usually primary
infection happens early in childhood and it is followed by
persistence of the virus throughout life (Klein, 1994). EBV is
also one of the most powerful immortalizing agents for B
lymphocytes in vitro and it is strongly associated with a
number of malignancies, including: Hodgkin's disease (HD),
nasopharyngeal carcinoma (NPC), and post-transplant lym-
phoproliferative disorder (PTLD) (Dolcetti and Masucci, 2003;
Klein, 1998; Raab-Traub, 2002; Rickinson and Kieff, 2001).
The pattern of antigen expression in EBV-positive tumors is
limited to just a few latent antigens. Infected cells break down
these viral antigens on a continuous basis according to the
half-life of each individual protein. In addition, defective⁎ Corresponding author. Fax: +1 418 691 5439.
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doi:10.1016/j.virol.2006.10.013ribosomal products of viral origin are also degraded. The
process occurs in the cytosol where a mixture of peptides is
generated by the proteasome, which are then translocated into
the endoplasmic reticulum (ER) by the transporter associated
with antigen-processing (TAP) heterodimer (Yewdell, 2001).
Incoming peptides are subsequently loaded onto nascent major
histocompatibility complex (MHC) molecules by the loading
complex. The tri-molecular structure formed by the β2
microglobulin (β2m), MHC class I heavy chain and the
peptide achieves the necessary stability to migrate to the cell
surface, where it will constitute the ligand for the T cell
receptor (Yewdell, 2001). Receptor-mediated recognition of
infected cells by MHC class I-restricted cytotoxic T lympho-
cytes (CTLs) plays a major role in the anti-EBV immune
response.
Given the self-inhibition of synthesis and antigen presentation
by the ubiquitous EBV nuclear antigen 1 (EBNA1) (Levitskaya
et al., 1995; Yin et al., 2003), attention has been focused on the
latent membrane proteins (LMP1, 2A and 2B) as alternative
sources of CTL epitopes for the immunotherapy of EBV-positive
tumors such as NPC, HD and PTLD (Brooks et al., 1992; Frisan
et al., 1995; Rickinson and Kieff, 2001; Straathof et al., 2005).
Table 1
HLA-A⁎0201 binding peptides
a Half-time in minutes of peptide-HLA-A*0201 dissociation as calculated by
the BIMAS software (http://bimas.dcrt.nih.gov/).
b CTL epitope prediction score as calculated by the SYFPEITHI software
(http://syfpeithi.bmi_heidelberg.com/).
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the LMPs, only subdominant specificities have been identified
so far (Chapman et al., 2001; Duraiswamy et al., 2004; Khanna et
al., 1996; Lautscham et al., 2001, 2003a, 2003b; Lee et al., 1993,
1996, 1997; Meij et al., 2002; Straathof et al., 2005). Future
attempts to enlarge the list of therapeutically useful CTL epitopes
could benefit from predictive pre-screening algorithms such as
the widely used BIMAS (Bioinformatics and Molecular
Analysis Section of the National Institutes of Health) (Parker
et al., 1994) and SYFPEITHI (Rammensee et al., 1999). The
former software ranks potential epitopes according to the
theoretical half-life of MHC-I/peptide/β2m complexes. The
latter classifies candidate peptides in function of the presence of
MHC anchor motifs.
Another way to facilitate the isolation of anti-LMP CTL
specificities is to increase antigen presentation. There have
been a few attempts to use dendritic cells (DCs) to improve the
generation of EBV specific T lymphocytes in vitro. DCs are
professional antigen-presenting cells (APCs) that can prime
resting and naive T lymphocytes and are central to the
induction and regulation of adaptive immunity (Banchereau et
al., 2000). Dendritic cells were loaded with viral peptides or
infected with antigen-carrying vaccinia or adenoviral vectors,
and used for in vitro stimulation of T cells (Bollard et al.,
2004; Gahn et al., 2001; Lin et al., 2002; Ranieri et al., 1999;
Redchenko and Rickinson, 1999; Subklewe et al., 2001).
These studies showed that the bias toward the reactivation of
memory responses against immunodominant epitopes was less
evident than in lymphoblastoid cell line (LCL)-based stimu-
latory protocols.
Antigen presentation can also be artificially enhanced by
cross-linking peptides to MHC molecules. Although this
strategy was shown to induce CTLs in vivo (Romero et al.,
1994), it requires a chemical modification that may affect
peptide/MHC binding and may elicit a response specific to the
altered molecule. This limitation was bypassed by directly
tethering the antigenic peptide to the MHC complex (Kozono et
al., 1994). The structure of the groove of class II MHC
molecules is more likely to accommodate longer peptides and
was shown to allow the attachment of linker molecules
(Toshitani et al., 1996). More surprising was the finding that
MHC class I heterodimers, having both ends of the groove
closed, also allow the carboxy-terminal extension of the peptide
(Mottez et al., 1995; White et al., 1999). Membrane-associated
forms of antigenic peptides tethered to class I and class II MHC
complexes were efficiently recognized by lymphocytes carrying
the specific TCR (Ignatowicz et al., 1995; Toshitani et al., 1996;
Uger et al., 1999).
The therapeutic importance of subdominant epitopes is not
necessarily diminished by their suboptimal status, provided that
they are generated and retain their target potential in infected
cells, and that there are circulating T cells carrying the relevant
TCRs (Elkington et al., 2003; Wallace et al., 1999). We
reasoned that by combining the highly efficient antigen-
presenting capacity of dendritic cells with the constitutive
expression of a synthetic peptide–MHC complex of enhanced
stability we could provide enough stimulus to expand Tlymphocytes directed to suboptimal CTL epitopes (STE) that
form unstable surface MHC complexes. This article describes a
new CTL epitope in LMP2 that was identified by using this
strategy.
Results
Design of peptide–β2 microglobulin fusion molecules
Having set as a goal the isolation of T cells reactive to
suboptimal epitopes in LMP2, we have arbitrarily defined STE
as being any peptide sequence that possessed anchor residues
for HLA-A⁎0201 binding and formed MHC complexes with a
half-life shorter than 40 min as predicted by the BIMAS
software. This definition of suboptimal peptides is solely based
on the algorithm calculations and intentionally excludes T cell
epitopes for which subdominance is dictated by parameters
other than MHC stability. First, we have screened the LMP2
amino acid sequence for HLA-A⁎0201 binding peptides with
the SYFPEITHI software. Selected peptides were then scored
by the BIMAS algorithm. The peptide LLLIVAGIL (LMP2
residues 396–404, from now on referred to as LLL) met the
STE specifications: a) the leucines in positions two and nine
function as anchor residues (SYFPEITHI score: 24), and b) the
predicted half-life for LLL–MHC complexes according to
BIMAS is 7.162 min (Table 1). The well-characterized GIL
epitope (Bednarek et al., 1991), derived from the influenza
matrix protein, residues 58–66, was chosen as a control. GIL
scores 30 for binding in SYFPEITHI and forms MHC
complexes with a predicted half-life of over 550 min according
to BIMAS (Table 1).
Algorithm predictions were confirmed by peptide binding
assays in TAP-deficient cells. We found that A2/hβ2m-RMA-S
and T2 cells loaded with the synthetic GIL peptide had a surface
MHC half-life longer than 12 h. However, in agreement with its
predicted very short MHC life span, the LLL epitope failed to
stabilize surface HLA-A⁎0201 molecules in both cell lines even
at concentrations as high as 10−4 M. The results obtained with
A2/hβ2m-RMA-S are shown in Fig. 1. The surface half-life of
“empty” HLA-A⁎0201 molecules in A2/hβ2m-RMA-S cells
was about 2 h as expected for RMA-S cells that express the
human β2m (Anderson et al., 1993).
Fig. 3. Rescue of MHC surface expression by peptide–β2 microglobulin fusion
molecules. The β2m-negative DLD-1 cell line was transduced with the LV–
LLLβ2mF, LV–β2mFΔA and LV–β2mFΔB viruses and analysed by FACS as
described in Materials and methods.
Fig. 1. Stability of peptide–MHC class I complexes in TAP-deficient cells. The
A2/hβ2m-RMA-S cells were generated as described in Materials and methods.
These cells were loaded overnight with the LLL or GIL peptide at 26 °C at a
10−4 M concentration, washed, incubated at 37 °C in presence of Brefeldin A,
and the HLA-A*0201 surface expression was checked by FACS analysis over
time. The decay at 37 °C of “empty”MHCmolecules induced at 26 °C in absence
of exogenous peptide is illustrated by the dashed line. The % mean fluorescence
intensity (% MFI) was calculated with respect to time 0 (% MFI=value at
indicated time÷value at time 0×100). Each point represents the average
obtained from four independent experiments.
255A. Lalonde et al. / Virology 361 (2007) 253–262We have used the coordinates from the crystal structure of
an HLA-A2–calreticulin peptide complex to design a linker,
Gly5(GlySerGly)2(GlySer)2, that fuses the putative LMP2
CTL epitope or the control peptide to the N-terminal end of
the β2 microglobulin (Collins et al., 1994). The genes
encoding the fusion proteins have been cloned into a
lentiviral vector and subsequently used to transduce dendritic
cell precursors (Fig. 2). This vector has a deletion in the 3′
long terminal repeat (LTR) and therefore the 5′ LTR
becomes transcriptionally silent upon reverse transcription
and integration. Only the transgene of interest (encoding theFig. 2. Vectors encoding peptides in various formats. The peptides were
expressed in fusion to the amino-terminal end of the β2 microglobulin or to
the carboxyl end of an ER signal sequence as described in Materials and
methods. The transgenes encoding the chimeric molecules were cloned into
a lentiviral vector as illustrated here. Besides the series of LLL vectors
shown in the figure, an additional series were constructed for the GIL
peptide (pLV–GILβ2mF and pLV–ERGIL), TWQ peptide (pLV–β2mFΔA),
and SII peptide (pLV–β2mFΔB).peptide–β2m) is constitutively transcribed from the internal
PGK promoter in transduced cells.
Peptide–β2 microglobulin fusion molecules are functional
The colorectal carcinoma DLD-1 cell line was used to test
the expression of the LLL fusion protein. These cells are β2m-
deficient and do not express surface MHC class I molecules.
They were transduced with the lentiviral vector LV–LLLβ2mF
and analysed by FACS. Two additional DLD-1 sublines
carrying β2m fusion molecules encoding for peptides lacking
suitable anchor residues to HLA-A⁎0201 were also tested:
β2mFΔA and β2mFΔB. The former contains a peptide with an
unfavorable tryptophan in position 2 while the latter has a
peptide with an unfavorable glycine in position 9. Fig. 3 shows
that the LLL chimeric protein binds the DLD-1 endogenous
HLA-A⁎0201 heavy chain in a stable fashion and rescues its
surface expression. The β2m fusion format per se is notFig. 4. Stability of MHC class I expression on the cell surface induced by
LLLβ2 microglobulin fusion molecules. The β2m-negative cell line DLD-1 was
transduced with LV–LLLβ2mF or LV–GILβ2mF, treated with cycloheximide,
incubated at 37 °C, and analysed over time for MHC surface expression by
FACS. The half-lives of the MHC complexes formed by the two-peptide
fusions are indicated. Each point represents the average obtained from four
independent experiments.
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destabilizes the resulting MHC complexes and completely
abolishes surface expression.
MHC complexes formed with the LLLβ2m fusion protein are as
stable as complexes containing the immunodominant GIL
peptide in a β2m fusion format
Given the demonstrated ability of LLLβ2m fusion molecules
to rescue HLA-A⁎0201 expression in a β2m-negative cell
background, we have decided to dissect further this observation
by measuring the surface half-lives of rescued MHC class I
complexes. Protein translation was inhibited by cycloheximide
treatment of DLD-1 cells, and the surface expression of HLA-
A⁎0201 molecules was analysed by FACS with the relevant
antibody at several time points. Fig. 4 shows that HLA-A2–
LLLβ2m fusion complexes were quite stable with a half-life of
14.5 h. Similar complexes formed with the GIL peptide–β2Fig. 5. Cytolytic activity of anti-LLLT cell effectors. (A) Recognition of cells expres
the HLA-A2-positive donor E2 (A2, B49, Cw7) were tested for their ability to lyse th
to the amino-terminal end of the β2 microglobulin. The DLD-1 subline carrying the
anchor to HLA-A*0201 was used as a control. (B) Recognition of peptide-loaded
concentration or no peptide (DMSO) in serum-free medium at 37 °C for 2 h. The
4 additional hours. (C) Recognition of autologous blasts constitutively expressing th
ability to lyse autologous blasts constitutively expressing a minigene-encoded LLL
negative control in two of the assays. Blasts transduced with an empty vector were u
histogram columns in panels A–C. The mean of four independent chromium releasmicroglobulin chimeric molecules were also long-lived
(19.4 h). These results contrast sharply with the picture obtained
by the predicted peptide–MHC dissociation rates (Table 1) and
stabilization assays in TAP-deficient cells (Fig. 1).
Engineered dendritic cells are capable of stimulating anti-LLL
T lymphocytes in vitro
Next, we have engineered dendritic cells to express
constitutively the peptide–β2 microglobulin fusion proteins.
Immature DCswere prepared frommonocytes obtained from the
peripheral blood of the HLA-A2-positive healthy EBV carrier
E2. Monocytes were first transduced with LV–LLLβ2mF viral
supernatants. Transduction efficiencies of 20% were regularly
obtained as assessed by parallel infections with a GFP control
lentiviral vector (data not shown). Gene-modified DC precursors
were then induced to differentiate, and used to stimulate
autologous peripheral T lymphocytes as described in Materialssing the LLL peptide in a β2m fusion format. LLL-specific T lymphocytes from
e β2m-negative DLD-1 cell line constitutively expressing the LLL epitope fused
β2mFΔA fusion which encodes a peptide with an unfavorable amino-terminal
PHA blasts. Target cells were pre-incubated with the LLL peptide at 10−4 M
n, they were extensively washed, and further incubated with the CTL line for
e LLL epitope. LLL-specific T lymphocytes from donor E2 were tested for their
epitope. Autologous blasts transduced with the LV–ERGIL vector were used as
sed in the other two occasions. The effector/target ratios are indicated below the
e experiments is presented.
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1 cells expressing the LLLβ2m fusion protein as shown in
Fig. 5A.
Exogenous LLL peptide sensitization of target cells to lysis by
CTL
Although stable on the cell surface, MHC complexes in
which the peptide–β2 microglobulin fusion protein participates
could adopt an unusual conformation. Therefore there was a
possibility that antigen receptors that recognize the chimeric
ligands would fail to recognize MHC complexes loaded with
the native LLL peptide. We reasoned that despite the very
short predicted dissociation half-time of LLL–MHC com-
plexes, killing of peptide-pulsed cells could be observed if
sufficiently high concentration of exogenous peptide were
used. However, modest levels of peptide sensitization of
autologous PHA blasts were achieved even at concentrations
as high as 10−4 M. Fig. 5B summarizes the results of
experiments in which killing of pre-coated cells were about
10% above background.Fig. 6. Recognition of EBV-infected cells and frequency of peptide-specific T lymph
engineered dendritic cells. CTL lines have been isolated from the HLA-A2-positiv
Materials and methods. The HLA-A2-negative cell line E6-LCL (A1, 11/B49, 55
independent experiments is presented. The effector/target ratios used are indicated. (B
loaded dendritic cells. The % specific lysis obtained in Chromium release assays is pr
used are indicated. (C) Frequency of LLL-reactive T cells in PBMCs. The frequen
ELISPOT assay as described in Materials and methods. The results are presented
performed in triplicate.A minigene-encoded LLL peptide forms MHC complexes that
can be engaged by the TCR of anti-LLL T lymphocytes
If our results indicate that the LLL peptide is inefficient to
sensitize PHA blasts to lysis by LLL-specific T cells when
provided exogenously, they do not exclude the possibility that a
better sensitization could be achieved if the peptide would be
produced endogenously in a constitutive fashion. To address
this issue, PHA blasts were prepared from the peripheral blood
from donor E2, and transduced with the lentiviral vector LV–
ERLLL presented in Fig. 2. Transduction efficiencies of 60%
were regularly obtained as revealed by parallel infections with a
GFP vector (data not shown). PHA blasts expressing the LLL
epitope fused in its amino-terminal end to the adenoviral ER
translocation signal peptide (Sherritt et al., 2001) were used as
targets in cytotoxicity assays. Cleavage of this product by signal
peptidases would release LLL for loading of nascent HLA-A2
heavy chains in the ER. Fig. 5C shows that the same CTL line
that recognized the LLL epitope in a β2m fusion format can also
lyse targets expressing MHC complexes formed with the
minigene-encoded LLL peptide.ocytes. (A) Recognition of LCL by LLL-specific T lymphocytes generated with
e donor E2, and used in standard 4 h chromium release assays as described in
/Cw3) and the autologous LCL have been used as targets. The mean of four
) Recognition of LCL by LLL-specific T lymphocytes generated with peptide-
esented as the mean of three independent experiments. The effector/target ratios
cy of epitope-specific T cells in peripheral blood was analysed by the IFN-γ
as the mean number of spots/106 PBMCs from two independent experiments
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It remained to be demonstrated that the LLL peptide could be
generated in EBV-infected B cells. Furthermore it was
necessary to show that the number of MHC complexes formed
with the wild-type LLL sequence, as well as their half-lives on
the surface of EBV-infected cells, could provide sufficient
ligand stimulation to trigger the effector function of anti-LLLT
lymphocytes. Fig. 6A summarizes the results of cytotoxicity
assays performed with anti-LLL CTL lines generated by in vitro
stimulation with DCs expressing the LLLβ2m fusion molecule.
These CTL lines were also tested against a panel composed of
six HLA-A2-matched and mismatched LCLs yielding similar
results (data not shown). Anti-LLL T lymphocytes consistently
killed the HLA-A2-matched lines and failed to kill HLA-A2-
negative control lines.
Next, we have tested if anti-LLL T lymphocytes could be
isolated in vitro by using peptide-coated dendritic cells as
stimulators. To our surprise, the dendritic cells loaded with
exogenous LLL could expand T cells efficiently. Furthermore
the effector lymphocytes also displayed cytolytic activity
against the autologous LCL as shown in Fig. 6B.
Frequency of peptide-specific T lymphocytes in peripheral
blood
Effector T cell populations could be obtained after two
rounds of in vitro stimulation, which suggests the existence of
a reasonable peptide-specific T cell precursor frequency. In
order to examine this possibility, we have used the IFN-γ
ELISPOT assay to assess the number of LLL-reactive T cells in
PBMCs from donor E2 and five additional individuals.
Contrary to our assumption, Fig. 6C shows that the HLA-A2
positive EBV carriers had low frequencies ranging from 7 to 23
LLL-specific T cells/106 PBMCs. The EBV seronegative donor
who was HLA-A2-positive (N1) and the EBV carrier who
lacked HLA-A2 (E5) did not show any LLL-specific reactivity
in their PBMCs. Circulating anti-LLL T lymphocytes in donor
E2 were detectable yielding an average of 11 spots/106
PBMCs.
Discussion
Subunits of multimeric proteins can be assembled in single-
chain format using synthetic spacers. This strategy has proven
to be successful for a number of proteins such as antibodies
(Huston et al., 1988), and class I (Berko et al., 2005; Margalit et
al., 2006; Tafuro et al., 2001; Toshitani et al., 1996; Uger et al.,
1999) and class II (Crawford et al., 1998) MHC molecules. It
has been shown that covalent coupling of an antigenic peptide
to the MHC heavy chain (Toshitani et al., 1996) or β2
microglobulin (Margalit et al., 2003; Tafuro et al., 2001; Uger
and Barber, 1998) can form efficient CTL target structures.
However the potential of antigen-presenting cells expressing
these chimeric molecules to expand cytotoxic T lymphocytes in
vitro has not yet been fully addressed. Furthermore only peptide
sequences already defined as T cell epitopes or their variantshave been used in earlier studies. Here we describe a new CTL
epitope in the LMP2 protein: LLL. T lymphocytes reactive to
this epitope were detected in the peripheral blood of four EBV-
seropositive healthy individuals. Autologous dendritic cells
constitutively expressing the LLLβ2m molecule were capable
of expanding in vitro HLA-A2-restricted anti-LLL T lympho-
cytes from peripheral blood. These T cells recognized MHC
complexes formed by fusion molecules expressed in β2m-
negative DLD-1 cells as well as “native” MHC complexes
formed by LLL peptides in LCLs. Taking into consideration the
predicted half-time of dissociation, the β2m fusion format
increased by two orders of magnitude the life span of LLL–
MHC complexes on the cell membrane.
Our original assumption was that the β2m fusion format was
essential for the expansion of LLL-specific T cells in vitro. To
our surprise, we found that peptide-loaded dendritic cells were
also capable of expanding T lymphocytes. Furthermore these
effector cells could also kill EBV-infected lymphoblastoid cells.
It remains to be seen if engineered DCs would prove to be
better stimulators in vivo. In support of this prediction,
engineered cells will present the peptide–β2m molecule
constitutively for as long as the DCs live in vivo. The specific
antigen presentation in peptide-loaded dendritic cells is bound
to dissipate faster as it depends on the kinetics of decay of
MHC complexes and not on the lifespan of the cell. Moreover,
the lentiviral vectors used in this approach do not generate
“antigenic noise”. No protein of lentiviral origin is produced
after proviral integration; only the LLLβ2m fusion molecule
encoded by the transgene is produced in the engineered cells.
The potential of these gene-modified DCs in in vivo vaccination
will be subject of future studies.
The anti-viral CTL response varies considerably in magni-
tude from epitope to epitope and is often focused on a limited
number of antigenic targets (de Campos-Lima et al., 1997;
Levitsky et al., 1998). Some of the weaker T cell specificities
are rarely detected in vitro or in vivo (de Campos-Lima et al.,
1994; Lewicki et al., 1995; Wallace et al., 1999). The CTL
epitope that we describe here is likely to be low in the hierarchy
of immunodominance. Nevertheless it may elicit a measurable
response in conditions that augment its presentation. A number
of possible reasons for the subdominance of LLL can be
contemplated. The LLL peptide could be poorly generated in B
cells and thus have a limited chance to compete with more
dominant peptides for binding to HLA-A2. In addition, it could
be the consequence of a peptide-specific T cell repertoire shaped
by self-tolerance, or the result from the low T cell precursor
frequency found in EBV seropositive individuals; the number
of LLL-specific T lymphocytes in the peripheral blood of the
latter is up to ten-fold lower than that reported for immunodo-
minant EBV epitopes (Tan et al., 1999). It is also conceivable
that EBV-infected B cells are not capable of expanding
efficiently the LLL-specific T lymphocytes in vitro and in
vivo because of the suboptimal LLL presentation. The fact that
LLL specificities have not been identified before (by us and
others) despite the extensive use of LCLs as T cell stimulators
seems to support this assumption. Nevertheless the most likely
explanation for the observed subdominance is the intrinsic
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dendritic cell phenotype per se seems to be sufficient to
compensate for this instability as demonstrated by our ability to
isolate anti-LLL T cell effectors in vitro with peptide-loaded
DCs. The use of β2m fusion molecules would further contribute
to bypass this limitation by increasing the surface half-life of
MHC complexes. It is also likely to increase the absolute
number of LLL–MHC complexes on the cell membrane as the
complexes formed with other endogenous peptides can only use
the natural β2m molecule.
Regardless of the cause(s) of the suboptimal nature of the
LLL CTL epitope, there are T lymphocytes in the peripheral
blood of EBV-seropositive individuals that can be expanded in
vitro, and most importantly, that are capable of killing virus-
infected cells. Our findings highlight the potential of anti-LLLT
cell effectors for the immunotherapy of LMP2-positive tumors.
This is particularly relevant given the small number of viral
epitopes currently known to be presented in the context of
frequent restricting elements, only very few of them being
HLA-A*0201-restricted (Lautscham et al., 2003b; Straathof et
al., 2005). Taking into consideration that antigenic variation
may enable even stable viruses to evade the immune system
(Apolloni et al., 1992; de Campos-Lima et al., 1993), the
inclusion of less dominant peptides, such as LLL, in the
therapeutic arsenal would decrease our reliance on a limited
number of “stronger” epitopes for vaccination.
One could envisage that autologous anti-LLL T cells could
be expanded in vitro for passive immunotherapy of patients
with EBV-positive tumors. Most importantly, the engineered
dendritic cells are already a vaccine that could be directly used
in these individuals without the need of large-scale T cell
expansion in vitro.
Materials and methods
Cell lines and culture media
LCLs were established by in vitro transformation of B
lymphocytes with the B95-8 EBV strain. RMA-S cells were
kindly provided by Dr. Klas Karre, Karolinska Institute,
Sweden. The subline A2/hβ2m-RMA-S was generated in our
laboratory by retroviral transduction with vectors carrying the
HLA-A⁎0201 and human β2 microglobulin transgenes. DLD-1
and T2 cells were obtained from ATCC. T blasts were activated
with 0.5 μg PHA/106 cells (Sigma). All cell lines were kept in
complete medium: RPMI 1640 or Dulbecco's modified Eagle's
medium (Invitrogen) supplemented with L-glutamine, 100 U/
ml penicillin, 100 μg/ml streptomycin and 10% heat-
inactivated FBS (Bio Cell). All cytokines used were from
Peprotech.
Generation and transduction of dendritic cells
PBMCs were isolated by Ficoll gradient centrifugation
(Amersham Biosciences), resuspended in complete medium,
and incubated in 6-well plates at 1.5×107 cells/ml at 37 °C for
2 h. Adherent cells were transduced overnight with 1.5 ml viralsupernatant plus 1 ml fresh medium with 8 μg/ml polybrene
(Sigma). Cells were kept for 5–6 days in complete medium
supplemented with 1000 U/ml GM-CSF and 1000 U/ml IL-4.
DC maturation was induced with TNF-α treatment (1000 U/ml)
for 2 days. Half of the medium was renewed every 2–3 days.
Alternatively, DCs were generated by exposing the monocytes
to GM-CSF/IL-4 for 2 weeks before maturation with TNF-α.
DCs generated as indicated above were capable of efficient in
vitro stimulation of LLL-reactive T cells.
Generation of CTL lines
LLL-specific CTL cultures were obtained by stimulation of
lymphocytes with autologous DCs constitutively expressing
the LLLβ2m fusion molecule at a ratio of 50:1. T cells were
tested after two or three consecutive stimulations. The culture
media was supplemented with 20 U/ml IL-2. About 25 ng/ml
IL-7 was also used in the first stimulation. A similar
stimulatory protocol was used with peptide-loaded DCs,
except for the pre-treatment with peptide at a 50 μg/ml
concentration at 37 °C for 2 h.
Peptide synthesis and HLA-A⁎0201 stabilization assays in
TAP-deficient cells
Peptides were synthesized by the solid phase method,
using automated F-moc chemistry, at the NAPS unit,
University of British Columbia, Canada. The peptides were
dissolved in DMSO at a concentration of 10−2 M and further
diluted in PBS or culture medium to the desired final
concentration. TAP-deficient cells (A2/hβ2m-RMA-S and T2
cells) were first incubated overnight at 26 °C with the relevant
peptide at 10−4 M concentration in AIM-V serum-free
medium (Gibco). Then, they were extensively washed, and
further incubated at 37 °C in presence of 1 μg/ml Brefeldin A
(Sigma) for the indicated periods of time. The HLA-A⁎0201
surface expression was analysed by FACS with the antibody
BB7.2 (BD Biosciences) on a XL flow cytometer (Beckman
Coulter).
Generation of the peptide–β2 microglobulin fusion constructs
The leader–LLL–spacer domain was generated by anneal-
ing two pairs of partially overlapping complementary oligonu-
cleotides (I+ II and III+ IV). Hybridized products were first
treated with Vent polymerase (New England Biolabs) and
dNTPs to complete the double-stranded fragments. Primers
5BG: 5′-AGGAAGATCTATGTCTCGCTCCGTG-3′ and
JAC-RC: 5′-GCCTCTAGACCAGAAAGAGAG-3' were
used to amplify the I/II fragment (30 cycles: 94 °C for 1 min,
55 °C for 1 min and 74 °C for 1 min) while primers 3SC: 5′-
GCGCGGATCCTGACCCAC-3′ and JAC-1F: 5′-TGCTCTA-
GAGGCTATCCAG-3′ were used to amplify the III/IV
template (30 cycles: 94 °C for 1 min, 50 °C for 1 min and
74 °C for 1 min). The PCR amplifications (Vent) introduced
one XbaI restriction site in each amplicon. The I/II and III/IV
amplicons were first purified, digested with XbaI, re-purified,
260 A. Lalonde et al. / Virology 361 (2007) 253–262and then ligated using T4 DNA ligase (Invitrogen). The
complete leader–LLL–spacer synthetic sequence (I/II–III/IV)
contained a BamHI restriction site in its 3′ end that allowed its
ligation in frame with the β2m gene. A similar protocol was
used to generate the leader–GIL–spacer synthetic sequence,
except for the use of oligonucleotide V as the hybridization
partner for oligonucleotide IV (I/II–V/IV). The sequences of
the long oligonucleotides were: I. 5′-ATGTCTGCGTCCGTG-
GCCTTAGCTGTGCTCGCGCTACTCT-3′, II. 5′-CTGGA-
TAGCCTCCAGGCCAGAAAGAGAGAGTAGCGC-
GAGCA-3′, III. 5′-GAGGCTATCCAGTTATTACTGATTG
TCGCTGGCATACTCGGAGGTGGGGGA-3′, IV. 5′-
G CGCGGATCCTGACCCACC TGAGCCTCCT-
GATCCGCCTCCCCCACCTCC-3′, and V. 5′-GAGGCTATC-
CAGGGGATTTTAGGGTTTGTGTTCACGCTCG
GAGGTGGGGGA-3′. To obtain the cDNA encoding the β2m,
total RNAwas extracted from Jurkat cells using Trizol (Gibco),
and reverse transcribed with M-MLV reverse transcriptase
(Promega). The cDNA was PCR amplified with Vent using
primers 3B2: 5′-AGGAAGATCTTTACATGTCTCGATC-3'
and 5B2: 5′-GCGCGGATCCCGTACTCCAAAGATT-3′ for
33 cycles (94 °C for 1 min, 55 °C for 1 min and 74 °C for 1 min).
The β2m amplicon had a BamHI restriction site in its 5′ end. The
amplification product was purified, digested with BamHI, re-
purified, and ligated to the leader–LLL–spacer or leader–GIL–
spacer synthetic sequences. The DNA fragments encoding the
fusion molecules LLLβ2mF or GILβ2mF were cloned first in
pGEM-T (Promega) for DNA sequencing, and then subcloned into
theBamHI and SalI sites of the lentiviral vector pRRL–5pme (Dull
et al., 1998) to generate pLV–LLLβ2mF and pLV–GILβ2mF (Fig.
2). pLV–β2mFΔA and pLV–β2mFΔB have been constructed in
the same fashion but carry the sequences encoding for the peptides
TWQLNGEEL and SIINFKELG, respectively. The glycine in
pLV–β2mFΔB is derived from the linker. All Oligonucleotides
used in this work were purchased from AlphaDNA and IDT.
Generation of minigenes encoding CTL epitopes fused to an
ER translocation signal peptide
The synthetic DNA sequences encoding LLL or GIL fused to
the C-terminal end of the ER translocation signal peptide from
the adenovirus E3/19K glycoprotein were constructed as
follows: complementary oligonucleotides (VI, VII, VIII and
IX for ER–LLL) or (VI, VII, X and XI for ER–GIL) were first
phosphorylated with T4 polynucleotide kinase (New England
Biolabs). Then, they were annealed, treated with Vent
polymerase and dNTPs, purified, and incubated with T4 DNA
ligase. The ligation products were used as templates for PCR
amplifications with primers XII/IX for ER–LLL and XII/XI for
ER–GIL. The minigenes have been cloned and sequenced in
pGEM-T, and subsequently cloned into the BamHI and SalI
sites of pRRL–5pme to generate pLV–ERLLL and pLV–
ERGIL (Fig. 2). The oligonucleotide sequences used were: VI:
5′-CGCGGATCCATGAGGTACATGATTTTAGGCTTG-
CTCGC-3′, VII: 5′-AGCGCTGCAGACTGCCGCAAGGGC-
GAGCAAGCCTAAA-3′, VIII: 5′-GCAGTCTGCAGCGCT
TTATTACTGATTGTCGCTGGCATACTCTGAGTCGA-CACGC-3′, IX: 5′-GCGTGTCGACTCAGAG-3′, X: 5′-
GCAGTCTGCAGCGCTGGGATTTTAGGGTTTGTGTT-
CACGCTCTGAGTCGACACGC-3′, XI: 5′-GCGTGTCGA-
CTCACAC-3′, and XII: 5′-CGCGGATCCATGAGGTAC-3′.
Virus stock preparation
Lentiviral supernatants were generated in 293T cells by
transient transfection (Caron and Caruso, 2005). Three plasmids:
pMDLg/RRE, pRSV-rev and pMD.VSV-G were cotransfected
with either of the following plasmids: pLV–GILβ2mF, pLV–
LLLβ2mF, pLV–ERGIL, pLV–ERLLL, pLV–β2mFΔA or
pLV–β2mFΔB. The supernatants containing lentivirus were
harvested 48 and 72 h after transfection, filtered through a
0.45 μm filter, and frozen at −80 °C.
Cytotoxicity assays
The T cell cytotoxic activity was analysed in standard 4 h
51Cr-release assays as reported elsewhere (Gavioli et al., 1992;
Lee et al., 1996). The targets were labeled with Na51CrO4 for 2 h
at 37 °C. Tests were performed in triplicate.
Stabilization of HLA-A⁎0201 in DLD-1 cells
DLD-1 cells were transduced with either LV–LLLβ2mF,
LV–GILβ2mF, LV–β2mFΔA or LV–β2mFΔB viral super-
natants in presence of 8 μg/ml polybrene. The HLA-A⁎0201
surface expression was analyzed by FACS with the antibody
BB7.2 (BD Biosciences) on a XL flow cytometer (Beckman
Coulter). DLD-1 sublines that have regained HLA-A⁎0201
surface expression (DLD-1-LLLβ2mF and DLD-1-GILβ2mF)
were used for the stabilization assays. Cells were treated with
100 μg/ml cycloheximide, and the HLA-A⁎0201 surface
expression was evaluated at the indicated periods of time.
HLA-A⁎0201 stability was calculated using the following
equation: (mean fluorescence at the indicated time÷mean
fluorescence at time 0)×100%.
IFN-γ ELISPOT assay
The ELISPOT assay was performed as reported elsewhere
(Tan et al., 1999). Briefly, 96-well polyvinylidene difluoride
plates were precoated with anti-INF-γ 1-DIK monoclonal
antibody (Mabtech). 2.5×105 PBMCs were seeded in
triplicate wells with 10−5 M of the LLL peptide and
incubated overnight. Then, the cells were discarded and the
plates were further incubated with the biotinylated anti-INF-γ
monoclonal antibody 7-B6-1 (Mabtech) followed by strepta-
vidin-conjugated horseradish peroxidase. The frequency of
IFN-γ-producing cells was determined by counting the
number of colored spots under a dissection microscope after
treatment with the 3,3′,5,5′-tetramethylbenzidine substrate
(Mabtech). The peptide-specific response was calculated by
subtracting the number of spots in control wells consisting of
PBMCs exposed to culture medium+DMSO in absence of
peptide.
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